ArticleJournal of managed care & specialty pharmacy2021

Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.

Anuja Chatterjee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.